CD44v6 Is Associated with Tumor Aggressiveness and Chemoresistance in Bladder Cancer

Bladder cancer represents a significant clinical and public health challenge. This malignancy is characterized by a very high propensity for recurrence and progression, underscoring the critical need for novel biomarkers to enhance early detection, prognosis, and specific therapeutic strategies. In the quest for such biomarkers, the CD44 family, particularly its variant isoform CD44v6, has emerged as a molecule of interest due to its pivotal roles in tumorigenesis and cell migration. Here we present a comprehensive study that elucidates the expression patterns and functional significance of CD44 and CD44v6 in bladder cancer. Utilizing robust methodological frameworks that include gene expression analyses, immunohistochemistry for protein localization, and a series of in vitro and in vivo functional assays, we systematically investigate the roles of these glycoproteins in bladder cancer pathology. Our analysis demonstrates a strong association between either elevated CD44 or CD44v6 expression and adverse clinical outcomes. Functional investigations attribute enhanced proliferative, migratory, and invasive capacities of bladder cancer cells to CD44v6 expression, indicating its contributory role in tumor aggressiveness and, importantly, in resistance to cisplatin treatment. In summary, our study places CD44 and CD44v6 as key biomarkers and putative therapeutic targets in bladder cancer. By shedding light on their mechanistic roles in cancer progression, we pave the way for the development of targeted therapeutic strategies that could potentially improve patient management and outcomes in bladder cancer. Overall design: Analysis of bladder cancer patient samples, including both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients, embedded in FFPE, by means of RNASeq analysis. Differences between CD44 and CD44v6 expression were used for comparative analysis.

膀胱癌是一项严峻的临床与公共卫生挑战。该恶性肿瘤具有极高的复发与进展倾向，凸显了开发新型生物标志物以优化早期检测、预后评估及特异性治疗策略的迫切需求。在寻觅此类生物标志物的过程中，CD44家族（尤其是其变异异构体CD44v6）因在肿瘤发生与细胞迁移中发挥的关键作用而备受关注。本研究开展了一项系统性探究，阐明CD44与CD44v6在膀胱癌中的表达模式及功能意义。本研究采用了严谨的方法学体系，涵盖基因表达分析、蛋白质定位免疫组化检测，以及一系列体外（in vitro）与体内（in vivo）功能实验，系统解析了这两类糖蛋白在膀胱癌病理进程中的作用。分析结果显示，CD44或CD44v6的高表达均与不良临床结局显著相关。功能实验证实，膀胱癌细胞的增殖、迁移与侵袭能力增强均与CD44v6的表达相关，提示其在肿瘤侵袭性及顺铂治疗耐药性中具有推动作用。综上，本研究确立了CD44与CD44v6作为膀胱癌关键生物标志物与潜在治疗靶点的地位。通过揭示二者在肿瘤进展中的分子机制，本研究为开发靶向治疗策略铺平了道路，有望改善膀胱癌患者的临床管理与预后结局。总体实验设计：通过RNA测序（RNASeq）分析福尔马林固定石蜡包埋（FFPE）的膀胱癌患者样本，涵盖非肌层浸润性膀胱癌（NMIBC）与肌层浸润性膀胱癌（MIBC）两类患者；以CD44与CD44v6的表达差异作为比较分析的依据。